Hims & Hers Health (NYSE:HIMS – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.
A number of other analysts also recently issued reports on HIMS. Citigroup dropped their price target on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Jefferies Financial Group reduced their price objective on Hims & Hers Health from $31.00 to $24.00 and set a “hold” rating on the stock in a research report on Tuesday, November 10th. Bank of America decreased their price objective on Hims & Hers Health from $26.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday. Truist Financial raised their price objective on Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a report on Monday, August 24th. Finally, Morgan Stanley cut their target price on Hims & Hers Health from $28.00 to $25.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 10th. Three investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $30.80.
Read Our Latest Stock Analysis on Hims & Hers Health
Hims & Hers Health Trading Down 9.1%
Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.03). The business had revenue of $890.37 million for the quarter, compared to analysts’ expectations of $893.13 million. Hims & Hers Health had a negative return on equity of 9.62% and a negative net margin of 6.65%. Hims & Hers Health’s quarterly revenue was up 48.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.06 earnings per share. On average, equities research analysts anticipate that Hims & Hers Health will post -0.38 EPS for the current fiscal year.
Insider Buying and Selling at Hims & Hers Health
In other news, CFO Oluyemi Okupe sold 3,518 shares of Hims & Hers Health stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $18.53, for a total value of $65,188.54. Following the transaction, the chief financial officer owned 266,188 shares in the company, valued at approximately $4,932,463.64. The trade was a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 3,462 shares of the business’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $27.60, for a total value of $95,551.20. Following the completion of the sale, the insider directly owned 293,886 shares of the company’s stock, valued at approximately $8,111,253.60. This trade represents a 1.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 105,041 shares of company stock valued at $2,764,840. Corporate insiders own 11.76% of the company’s stock.
Hedge Funds Weigh In On Hims & Hers Health
Large investors have recently bought and sold shares of the stock. Versant Capital Management Inc lifted its position in Hims & Hers Health by 801.2% in the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after purchasing an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after purchasing an additional 319 shares during the period. GK Wealth Management LLC bought a new position in shares of Hims & Hers Health in the third quarter worth approximately $37,000. Compass Financial Management LLC bought a new position in shares of Hims & Hers Health in the second quarter worth approximately $50,000. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Hims & Hers Health in the second quarter worth approximately $147,000. 63.52% of the stock is owned by hedge funds and other institutional investors.
About Hims & Hers Health
Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.
Featured Stories
- Five stocks we like better than Hims & Hers Health
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
